|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001418,
umls-concept:C0014871,
umls-concept:C0031268,
umls-concept:C0032743,
umls-concept:C0087111,
umls-concept:C0181090,
umls-concept:C0282460,
umls-concept:C0302614,
umls-concept:C0311400,
umls-concept:C0871261,
umls-concept:C1516048,
umls-concept:C1704632,
umls-concept:C1706050,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-9-3
|
|
pubmed:abstractText |
In patients with locally advanced adenocarcinoma of the oesophagogastric junction (AEG), early metabolic response defined by 18-fluorodeoxyglucose-PET ([(18)F]FDG-PET) during neoadjuvant chemotherapy is predictive of histopathological response and survival. We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1470-2045
|
|
pubmed:author |
pubmed-author:BeckerKarenK,
pubmed-author:BredenkampRainerR,
pubmed-author:FinkUlrichU,
pubmed-author:HöflerHeinzH,
pubmed-author:HerrmannKenK,
pubmed-author:KrauseBernd-JoachimBJ,
pubmed-author:LordickFlorianF,
pubmed-author:LorenzenSylvieS,
pubmed-author:OttKatjaK,
pubmed-author:PeschelChristianC,
pubmed-author:SchusterTiborT,
pubmed-author:SchwaigerMarkusM,
pubmed-author:SiewertJörg RJR,
pubmed-author:SteinHubert JHJ,
pubmed-author:WeberWolfgang AWA,
pubmed-author:WiederHinrichH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
797-805
|
|
pubmed:meshHeading |
pubmed-meshheading:17693134-Adenocarcinoma,
pubmed-meshheading:17693134-Aged,
pubmed-meshheading:17693134-Algorithms,
pubmed-meshheading:17693134-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17693134-Combined Modality Therapy,
pubmed-meshheading:17693134-Esophageal Neoplasms,
pubmed-meshheading:17693134-Esophagogastric Junction,
pubmed-meshheading:17693134-Feasibility Studies,
pubmed-meshheading:17693134-Female,
pubmed-meshheading:17693134-Fluorodeoxyglucose F18,
pubmed-meshheading:17693134-Humans,
pubmed-meshheading:17693134-Male,
pubmed-meshheading:17693134-Middle Aged,
pubmed-meshheading:17693134-Neoadjuvant Therapy,
pubmed-meshheading:17693134-Positron-Emission Tomography,
pubmed-meshheading:17693134-Prognosis,
pubmed-meshheading:17693134-Survival Rate
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
|
|
pubmed:affiliation |
Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany. florian.lordick@med.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
